Table 2.
DOX Concentrations per Group and Organ
| Group | Heart | Liver | Spleen | Kidney | Lung |
|---|---|---|---|---|---|
| iv DPPG2-TSL-DOX (low dose) + HT | 0.86 ± 0.06 | 2.29 ± 0.61 | 3.90 ± 0.71 | 4.21 ± 0.64 | 2.60 ± 0.69 |
| iv DPPG2-TSL-DOX (low dose) + ext. HT | 1.12 ± 0.08 | 2.19 ± 0.20 | 5.13 ± 0.36 | 4.59 ± 1.10 | 6.12 ± 1.76 |
| iv DPPG2-TSL-DOX (low dose) - HT | 0.77 ± 0.14 | 1.73 ± 0.27 | 4.47 ± 0.45 | 3.61 ± 0.47 | 1.40 ± 0.49 |
| iv free DOX (low dose) + HT | 1.68 ± 0.17 | 3.79 ± 0.58 | 3.63 ± 0.57 | 10.07 ± 1.54 | 2.26 ± 0.35 |
| iv DPPG2-TSL-DOX (full dose) + HT | 2.85 ± 0.34 | 10.03 ± 1.52 | 22.90 ± 5.06 | 21.03 ± 3.38 | 18.57 ± 4.06 |
| intraves DOX (full dose) - HT | <0.20* | <0.20* | <0.20* | 0.22 ± 0.02 | <0.20* |
| intraves DOX (full dose) + HT | <0.20* | <0.20* | <0.20* | 0.24 ± 0.04 | <0.20* |
Notes: Concentrations are ± standard error of mean in ng/mg; *Represents below limit of quantification.
Abbreviations: DOX, doxorubicin; DPPG2, 1.2-dipalmitoyl-sn-glycero-3-phosphodiglycerol; HT, hyperthermia; intraves intravesical; iv, intravenous; TSL, thermosensitive liposomes.